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Abstract 
Universal Tumor Screening for Lynch Syndrome: Investigation of Patient Reported 
Distress Levels 
 
Samantha Victoria Fernandes Afonso, MS 
 
University of Pittsburgh, 2019 
 
Abstract 
 
Lynch syndrome is a hereditary cancer predisposition from pathogenic variants in 
mismatch repair (MMR) genes, conferring an increased lifetime risk of colorectal cancer up to 
70%. Many healthcare facilities utilize universal tumor screening (UTS) of colorectal tumors 
through microsatellite instability (MSI) testing or immunohistochemistry (IHC) staining for MMR 
protein expression. These screening tests identify individuals at risk to carry a pathogenic variant 
in a Lynch related gene. This pilot study analyzed levels of patient distress among colorectal cancer 
patients who had UTS or who had been diagnosed with colorectal cancer before the age of 50, and 
subsequently underwent genetic counseling at the University of Pittsburgh Medical Center 
(UPMC) Hereditary GI Tumor Program, and patients with normal UTS who were seen in the 
surgical oncology center without genetic counseling. Patients were asked to complete a series of 
validated questionnaires (PHQ-8, GAD-7, IES-R) to evaluate their levels of depression, 
generalized anxiety, and trauma associated with their diagnosis of cancer at three points. For those 
who received genetic testing, the MICRA questionnaire was completed after receiving genetic test 
results to evaluate impact of the results on distress. Given the small number of participants (n=23), 
nonparametric tests were used to assess the differences in patient distress over time. Levels of 
distress were measured in both groups at all three time points. For a given individual, there was no 
statistically significant difference in any distress scores across the three time points within the case 
group. Analysis of baseline distress between patients in the case group and the control groups were 
not statistically significant, however the mean values of patient distress trended higher across the 
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case sample compared to the control sample. The impact of test result type on distress levels did 
not identify a statistically significant difference (p=0.727). While not statistically significant, 
increased levels of uncertainty were observed in the case group after receiving genetic testing 
results as compared to controls. Understanding the impact of UTS on patient-associated distress 
has important public health implications and may assist in patient support to alleviate 
psychological distress and further the assessment of UTS as a public health application.  
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1.0 Literature Review 
1.1 Colon Cancer 
1.1.1  Epidemiology of Colon Cancer 
Worldwide, colorectal cancer (CRC) accounts for more than 880,000 deaths per year and 
is the third most common malignancy in the United States.1 As the most preventable, but least 
prevented type of cancer, the 5-year relative survival rate of CRC is between 64-67%.2; 3 Early-
detection through public health screening (beginning at age 50 years) has had a role in the reduction 
in the prevalence and mortality of CRC through both the early removal of precancerous growths 
known as polyps, and the increased detection of CRC at early more treatable stages.3 Although 
CRC remains a common cancer, the incidence and mortality rates from CRC in older populations 
have seen dramatic decline within the past 30 years.4 However, while older populations have seen 
a continued decline in the incidence of invasive CRC, those aged 40-49 have seen an increase in 
incidence and mortality from CRC.3; 4  
1.1.2  Hereditary Colon Cancer 
Hereditary cancer syndromes are caused by inherited mutations that increase an 
individual’s susceptibility to cancer development. When considering all CRC, approximately 10% 
are due to a hereditary predisposition.5 Inherited forms of CRC are seen in multiple generations, 
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present with distinct histological features, and are more likely to be diagnosed before the age of 
50, which is the recommended age to begin screening through colonoscopies.5  
1.1.3  Lynch Syndrome 
Lynch Syndrome (LS) is the most common form of hereditary CRC.5  Lynch Syndrome 
accounts for approximately 3% of all hereditary CRC and has been shown to be present in about 
8% patients diagnosed with CRC before the age of 50. 5 Four DNA mismatch repair (MMR) genes 
are associated with LS: MLH1, MSH2, MSH6, PMS2 as well as a gene associated with the MSH2 
promoter hypermethylation: EPCAM.  
Lynch syndrome is an autosomal dominant condition and therefore, patients with Lynch 
syndrome have a 50% chance of passing the affected gene to their children, and there is a 50% 
chance that their siblings carry the same variant. Individuals with a pathogenic variant in a Lynch 
syndrome related gene are not only at an increased lifetime risk for colon cancer but are also at 
increased risk for several other cancers.  
Lynch syndrome conveys a risk of colon cancer as high as 70%, with uterine (also known 
as endometrial) cancer risks following between 40-60%.6 Patients with Lynch syndrome are also 
at a 5-8% risk of stomach cancer, a 7% risk of ovarian cancer, a 6% risk of urinary tract cancers 
and a 2-4% risk of small bowel, pancreatic, or brain cancer.6 Risks associated with pathogenic 
variants in the MSH6 and PMS2 genes are lower than those associated with MSH2 and MLH1. 
There are also variant forms of Lynch syndrome, such as Muir Torre, and Turcot syndrome that 
are associated with extra dermatologic and CNS findings respectively. Given these known 
increased lifetime cancer risks, preventative screening and guidelines have been established to 
increase early detection.  
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For early detection of colon cancers, colonoscopies repeated every 1-2 years are 
recommended beginning at 20-25 years or 2-5 years prior to the earliest diagnosis of CRC in the 
family if before 25 years of age. Daily intake of 81mg of Aspirin has also been recommended as a 
chemopreventive agent to reduce risk of colonic adenomas, but the optimal dose and duration is 
uncertain.7 Prevention and screening guidelines similarly exist for the risk associated with extra-
colonic Lynch associated cancers.8 Endometrial biopsies, transvaginal ultrasounds, and serum CA-
125 levels may be recommended for women every 1-2 years, until a hysterectomy and bilateral-
salpingo oophorectomy can be completed.8 Oral contraception has also been indicated as a risk 
reducing agent for uterine and ovarian cancers.8 Annual urinalysis beginning at 30-35 years old 
for urinary tract cancer screening and upper endoscopy beginning at 40, every 3-5 years for 
stomach and small bowel cancer screening are also recommended for individuals with Lynch 
syndrome.8 If there is a history of a first degree relative with pancreatic cancer, then MRI or 
endoscopic ultrasound can be considered as a screening tool for pancreatic cancer.9 Treatment for 
Lynch related cancers can also differ based on the presence of tumor related histological features. 
These features are assessed as a part of the tumor screening program. 
1.1.4  Tumor Screening Techniques for Lynch Syndrome 
The loss of these MMR protein expression in solid tumors causes microsatellite instability 
(MSI), which could result from a germline mutation or acquired deficiency, so MSI testing can 
serve as a screening test for Lynch Syndrome. Similarly, immunohistochemistry (IHC) studies 
performed on a tumor can evaluate for loss of MMR protein expression. 
Historically, cases of LS were clinically diagnosed using the Amsterdam criteria, but nearly 
three-quarters of LS patients with an identifiable germline mutation fail to meet Amsterdam 
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criteria.10; 11  The use of MSI testing or IHC studies to identify MMR deficiency has been found to 
detect >90% of LS patients. 10; 12  As a result, the cancer genetics community has widely adopted 
universal tumor screening (UTS) of colorectal cancers for MMR deficiency.13   
In 2009, the Evaluation of Genetic Applications in Practice and Prevention (EGAPP) 
working group made the recommendation of UTS for all patients newly diagnosed with CRC, 
through MSI and/or IHC testing. These methods have been acknowledged as cost-effective and 
beneficial to patients.14 Routine analysis of other Lynch syndrome-related cancers such as ovarian, 
or sebaceous neoplasms have been studied and have found to be effective methods of identifying 
individuals requiring further genetic evaluation.15; 16 UTS through IHC has been found to have a 
diagnostic yield of 2.2% with a specificity and sensitivity of 93% and 100% respectively.17  Even 
with the recommendation for UTS by EGAPP, it has not been widely embraced.18; 19  A study of 
106 respondents within the Familial Cancer Risk Counseling Special Interest Group of the 
National Society of Genetic Counselors identified that only 42.9% (24/59) of newly diagnosed 
endometrial or colorectal tumors were being automatically screened for Lynch Syndrome at their 
institutions.18 Additionally, some groups such as the NCCN indicate that histology is acceptable 
as a first line analysis to reduce the number of unnecessarily tested tumors, despite the fact that 
data has found that histologic features of MMR deficiency do not reliably predict the status of 
MMR proteins by IHC.20   
With the advent of UTS, there has been an increase in the number of patients being 
identified as having LS that lack obvious clinical features.18; 21; 22 This has important implications 
for the identification of families with increased risks for Lynch associated cancers. When a 
pathogenic variant is identified in an individual, cascade testing can begin to identify other family 
members at increased risk. Early identification of Lynch Syndrome can result in initiation of 
 5 
appropriate screening and prevention, leading to an increase in Lynch-cancer survival rates.15; 16 
Still, the identification of Lynch tumors has clinical application beyond understanding genetic risk. 
The WHO has determined that MMR deficient CRC is low-grade as they typically pursue a less-
aggressive clinical course than stage matched MMR-proficient tumors.19 This discovery of a 
difference in natural history of disease in MMR deficient tumors has resulted in a reconsideration 
of the appropriate treatment for different stage cancers. Chemotherapy will likely not be 
recommended when the tumor is MMR deficient and late-stage, and if it is given, then it is less 
likely to elicit a beneficial response in these patients.23-25 A recent study looked at a total of 43 
patients with CRC with MMR deficient status and found that MMR deficient CRC was resistant 
to chemotherapy25, confirming results from previous studies which similarly demonstrated 
negative response rate to fluorouracil chemotherapy in MMR deficient CRC.24  Pharmaceutical 
advances have led to the development of targeted MMR chemotherapeutic agents such as 
pembrolizumab (Keytruda). Pembrolizumab was approved by the FDA in 2017 for the treatment 
of unresectable or metastatic solid tumors that have been identified to have MSI or MMR 
deficiency, and is the first treatment to have been approved for a genetic marker rather than a solid 
tumor location.26 A total of 15 distinct cancer types were found in 149 patients that were enrolled 
across 5 clinical trials.26 The most common cancer types were Lynch associated: colorectal, 
endometrial, and other gastrointestinal cancers.26 Of the 149 patients who received pembrolizumab 
treatment there were 39.6% who showed a response.26 Pembrolizumab is thought to be effective 
against MMR deficient tumors, as these tumors have a high number of frameshift mutations.7 
These frameshifts are believed to incite an immune response through activation of PD-1.7 
Pembrolizumab works to block PD-1, which leads to the inhibition of the immune response, 
allowing the body to more effectively defend against cancer cells.7 
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It is well understood that there is a treatment specific advantage to the identification of MSI 
and MMR status, yet even though treatment may be tailored based on this information, patients 
are not always notified of their tumor study results.27 The explanation of benefits for families by 
identification of Lynch syndrome is associated with patient follow through with genetic testing 
and counselling by appropriate genetics providers. In a study of 1,108 patients at the Cleveland 
Clinic Health System, when results of tumor studies were reported in the traditional manner as a 
pathology addendum, only half of patients were referred to the appropriate genetics professional.27 
The lack of appropriate referrals raises an important consideration in UTS. Appropriate care and 
monitoring of Lynch families requires diagnosis of a pathogenic genetic variant in a Lynch 
associated gene. Ensuring accurate testing and interpretation of results for unaffected family 
members requires access to an affected family member’s genetic test result. While pathology 
reports from an affected family member can assist with assessment of risk and consideration of 
which potential Lynch genes to test, testing of unaffected members without testing of an affected 
member is limited in its interpretation. Likewise, while the pathology report might be available to 
the family in the medical record, the importance might not be fully understood if it was not 
discussed with the family while the patient was alive. Thus, while the traditional method of 
reporting is reliable for the pursuit of appropriate treatment, it has not been shown to be an adequate 
method for the referral of individuals for genetic testing as it does not provide complete 
information for families at risk for Lynch syndrome.  
1.1.5  Informed Consent for Universal Tumor Screening 
As with any medical procedure, informed and voluntary consent is required prior to genetic 
testing. Within the scope of genetic counseling there is special consideration of the importance of 
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providing informed consent to ensure complete understanding of potential ethical implications of 
genetic testing. This has been considered an important aspect of genetic testing in particular, as it 
has implications for knowledge about other family members outside of the individual pursuing 
testing. The American Society of Clinical Oncology published guidelines that indicate genetic 
testing should only be conducted with appropriate pre- and post- test counselling and should 
include a discussion of risks and benefits to the individual and their biological family members.28 
With the advent of the recommendation of UTS, there has been consideration within the healthcare 
community as to the requirement of explicit and informed consent for MSI and IHC tumor testing 
and its implications beyond cancer care.10; 18; 29 The implications of somatic mutations in 
conjunction with abnormal IHC testing are not always well understood by providers, including the 
implications for other extra-colonic Lynch-related cancers in family members presenting a 
potential difficulty with the responsibility of the provider to give informed consent. 30 Bombard et 
al., found that only 4/29 (14%) of National Cancer Institutes offered an opt-out from reflex 
testing.30 This process of opt-out testing is in line with the study of 245 individuals with MMR 
deficient CRC done by Ward et al., in 2013.29 This study demonstrated that approximately half 
(102/245, 42%) of patients for whom informed consent was provided for tumor testing declined to 
consent or did not provide a sample to learn their germline results.29  
There has been controversy surrounding the requirement of informed consent and pre- and 
post- test counselling for MSI and IHC testing among providers.30 Ultimately, it has been largely 
decided that informed consent is not an ethical prerequisite for either MSI or IHC screening for 
Lynch syndrome.30 This decision was made, largely on account of the associated knowledge that 
there is already informed consent gathered for the medical procedures (colonoscopies, surgeries 
etc.) that collect the samples for pathological evaluation.10 Rather, it has been proposed that 
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patients should be prepared for the possibility of a positive screening test and further testing 
recommendations prior to the procedure to collect a biopsy as part of the general informed consent 
process.10 The pre- and post- test counselling is considered when a positive result is returned after 
pathological analysis as further testing for LS is typically done through a referral to a genetic 
counselor, or genetics professional who can provide more information regarding the implications 
and informed consent for germline testing.   
1.2 Genetic Counseling 
As a profession, genetic counseling as defined by the National Society of Genetic 
Counselors (NSGC) is “the process of helping people understand and adapt to the medical, 
psychological, and familial implications of the genetic contribution to disease.”31 This definition 
underscores the patient-centered approach to personal healthcare provided by genetic counselors. 
Genetic counselors can work in a variety of subspecialty disciplines, including oncology, 
pediatrics, neurology, prenatal, or laboratory services. 
1.2.1  Genetic Counseling Outcomes 
As professionals in genetics and psychosocial counseling, genetic counselors are 
considered valuable members to medical teams to enhance patient care satisfaction and well-being 
as well as assist with appropriate test coordination resulting in decreased cost and liability to 
establishments. 32  
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   To demonstrate the benefits and efficacy of the profession, measurement of 
outcomes has become a priority for research. A seminal study by Redlinger-Grosse, 
et al. 33 developed a comprehensive list of outcomes based on the Reciprocal Engagement 
Model (REM) that examines the mutual participation of patients and genetic counselors  in 
the process of understanding and applying new information. Through their research they 
identified four main themes that arose: 
1. Patient Knowledge
2. Decision-Making
3. Patient Satisfaction
4. Psychological Adaptation
While there are no universal themes examined across genetic counseling outcome research,
the four main themes identified through Redlinger-Grosse, et al.33 provide a context for further 
research. As one of the aims of genetic counseling is enabling patients to make informed decisions, 
it is imperative that patients are able to understand specific genetic information related to their 
health. There is an expected increase in patient satisfaction with genetic counseling, as patients are 
given personalized sessions and are encouraged to make individualized healthcare decisions with 
support from their social systems and healthcare team. Ultimately, psychological adaptation is an 
important aspect of genetic counseling. As the name implies, genetic counselors are trained to 
anticipate, discuss, and support patients through the psychological and emotional implications of 
genetic testing and results. 34 Thus, it would be expected that with increased psychological support, 
patients are able to make informed decisions and experience less anxiety as well as improved 
communication within families and systems of support.33; 34  
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1.2.2  Self-efficacy and Empowerment 
Genetic counseling has been shown to result in an increased observance of medical 
management plans amongst patients34; 35 A study of 143 patients at a psychiatric genetic counseling 
clinic demonstrated a statistically significant increase in self-efficacy and empowerment after 
genetic counseling.36 These changes were not dependent on the results of genetic testing as the 
clinic does not provide genetic testing to these patients. A similar 2016 study found that genetic 
counseling led to improved levels of patient knowledge of genetic components of their health 
condition, and improved accuracy of risk perception when compared to patients receiving only an 
educational booklet.37 The 2004 meta-analysis by Braitwaite et al.38 indicated a statistically 
significant increase in knowledge and intervention in oncology based genetic counseling as 
compared to those with no genetic counseling. Brain et al. found that there was a statistically 
significant greater improvement in knowledge about breast cancer after receiving specialist genetic 
services. 39  
1.2.3  Genetic Counseling Compliance with UTS and LS 
A 2012 study by Cragun et al.40 found that genetic counseling and further germline genetic 
testing was supported by 67-72% individuals with abnormal colorectal IHC results, but that cost 
was a large aspect of consideration for these individuals. Irons et al.41 found that of uptake of 
genetic counseling at MD Anderson in individuals with an identified abnormal IHC results was 
35.7% overall, and 85.7% in patients with a family history of LS-related cancers, potentially 
identifying a system of self-selection for genetic counseling uptake.41 In a study of 1,108 colorectal 
cancers by Heald et al.27 it was found that more patients attended genetic counseling appointments 
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when the referral was facilitated by the genetic counselor rather than through the surgeon, and 
referral by a genetic counselor resulted in more patients who were correctly identified and tested 
positive for LS.27 Hunter et al. found that cost was a common barrier to the uptake of genetic 
testing (54%), and that overall, the distress associated with UTS was low.42 This demonstrates that 
patients are supportive of UTS, but the study failed to assess patient understanding of the 
implications of the results of further genetic testing. Alternatively, Manne et al.43 were able to 
incorporate educational material about genetic testing prior to UTS and found that 91% of 
individuals with a prior educational program about genetic counseling and testing chose to pursue 
genetic counseling after abnormal IHC results were returned.43 They also demonstrated that 
increased education prior to UTS did not increase levels of anxiety in participants.43  The findings 
of these studies suggest that individuals may have a variety of reasons for not pursuing follow up 
genetic testing after UTS.  While genetic counseling has generally shown to increase patient 
uptake, there seem to be a number of barriers to accessing genetic counseling and testing services. 
1.2.4  Impact of Genetic Test Results 
Genetic counseling addresses concerns that can be stressful and emotional for many 
individuals. Unlike most other conditions, inherited cancer syndromes typically have a known 
pattern of inheritance that can impact individuals’ self-concept and self-esteem.44; 45 It has been 
shown that women experience significantly different levels of psychological distress following 
BRCA1 mutation testing depending on the results of their testing.45 Significantly, positive results 
may present a difficult burden for individuals with a family history of inherited cancers that are 
often diagnosed at relatively-young ages.44 Bereavement and grief are common in familial cancer 
clinics as young adults may have lost parents to cancer at young ages.44 Patients’ beliefs of genetic 
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testing and results have been shown to change with increased knowledge through genetic 
counseling; while 76% of patients surveyed expressed interest in genetic testing at baseline, 
following genetic counseling 71% of women were still interested.46  
There is limited literature in regard to impact of tumor screening results on patient affect. 
Lindor et al.47, ascertained that of 414 CRC patients provided with education material about their 
MSI/IHC results, 307 participants (74%) decided to learn the results of their testing with the 
understanding of the ambiguity or inherent complexity of the information. Participants were 
interested in receiving their MSI results to help understand future family risk, help make an 
informed choice, and contribute to relevant research.47 Women with abnormal MSI results 
demonstrated a slight decrease in reported quality of life, whereas women with normal MSI 
reported no change in their self-rating of quality of life; alternatively, men with abnormal results 
showed a slight improvement in QOL whereas those men with normal results showed a slight 
decrease in self-reported QOL. None of the reported changes in QOL were statistically 
significant.47 The reported disparity between perceptions of QOL between men and women based 
on their CRC MSI results presents an open avenue of further research to better understand the 
impact of these results on psychological distress in patients. It is important to make the distinction 
that the impact of genetic testing is not considered an outcome of genetic counseling.33 The positive 
values of genetic counseling such as empowerment and self-efficacy have been shown to persist 
regardless of the genetic testing result. 36 Although there is a potential impact of genetic test results 
on an individual or family, the impact of genetic counseling on patient care should not be conflated 
with the impact of results and may assist with mitigating negative impacts from genetic test results. 
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1.3 Patient Distress 
1.3.1  Distress in Cancer 
As there has been a discernable impact documented from genetic test results on individuals 
psychological distress, the literature has also identified four attributes in relation to the concept of 
cancer-related psychological distress: depression, anxiety, fear, and feeling discouraged.48 Adults 
with a diagnosis of cancer who have undergone surgical treatment have demonstrated relevant 
levels of chronic stress which has implications for biologic effects.49 Data investigating 116 
patients having recently undergone surgical treatment for breast cancer had blood drawn prior to 
adjuvant therapy and demonstrated that the physiologic effects of stress inhibit cellular immune 
responses.49 Understanding the extent of psychological distress in cancer may have further 
implications as to the appropriate treatment required to combat various physiologic effects.49 
Albrecht & Rosenzweig estimated that at least 48.7% of patients with a hematologic malignancy 
experienced cancer-related distress.50 Patient cancer-related distress is not only associated with 
poor51 psychological outcomes for patients, but also for clinicians and family members providing 
care.50; 52 A cross-sectional survey of 354 cancer patients and 336 care-providers demonstrated that 
53.4% of patients and 45.2% of caregivers experienced significant levels of anxiety or depression 
through assessment of both clinical diagnosis and symptoms.53 Cancer status (stable disease, 
remission, metastatic, recurrent) was not found to be a significant predictor of psychosocial 
outcomes for these patients. They identified age, gender, marital status, treatment, work status, 
education and income as significant bivariate correlates for psychological distress predictors, 
representing important variables in consideration of further research.53  
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1.3.2  Distress in Cancer Genetic Testing 
Genetic risk information provides personalized assessments of risks for patients. As 
medicine moves toward an increasingly personalized approach, the consideration of the 
psychological impact of genetic test results is warranted. A 1996 study found that after controlling 
for level of education, women with breast cancer who had genetic counseling exhibited a 
statistically significant decrease in breast-cancer-specific distress at a 3-month follow up as 
compared with women who received generalized health education, and failed to demonstrate any 
statistically significant increase or decrease in generalized anxiety.54 More recent studies have 
demonstrated similar results, with statistically significant decline in levels of cancer-related 
distress during follow-up in breast cancer patients following genetic counseling.55 A study of 181 
female participants who accessed a cancer genetic counseling clinic confirmed that genetic 
counseling distinct from genetic testing was not a source of psychological distress.56 Further 
research in Spain has identified that cancer worry prior to genetic testing is predictive of genetic 
testing specific distress after results.57 Of individuals with a known familial mutation, 10–20 % of 
counselees demonstrated psychological problems after testing positive, after measurement at three 
time points.58 165  counselees with a 50% risk of testing positive for BRCA1/2 or Lynch syndrome 
were assessed for levels of emotional distress prior to genetic counseling.58 These measurements 
were taken at 2-3 days after receiving their test result, and again 4-6 weeks later.58 Those 
counselees with a positive result did not exhibit statistically significant increased levels of 
emotional distress, but did exhibit more cancer worries after learning of their test result.58Much of 
the research conducted thus far has focused on women pursuing testing for Hereditary Breast and 
Ovarian Cancer (HBOC).  Little other research has been conducted as to the perception of patient 
distress in relation to Lynch testing and therefore, this topic is worthy of further investigation. 
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1.4 Distress Measures 
1.4.1  PHQ-8 
Depression is one indication of an individual’s level of psychological distress. The Patient 
Health Questionnaire depression scale (PHQ-8) is a validated diagnostic measure for depressive 
disorders. The PHQ-8 has been assessed in epidemiological population-based studies as well as 
large clinical studies. A 2008 survey of 198,678 random-digit-dialed telephone participants found 
that the prevalence of current depression disorder was similar between diagnostic algorithms or 
through use of PHQ-8 score ≥10.59 The PHQ-8 consists of eight questions based on the DSM-IV 
diagnostic criteria for depressive disorders, and a final question based on assessing risk for suicide 
or self-harm. The scores may range from 0-24. The questionnaire asks respondents to rate the 
frequency of their emotions corresponding to different scenarios over the past two weeks on a 
Likert scale of 0-3, where 0 is “Not at all”, 1 is “several days”, 2 is “more than half the day”, and 
3 is “nearly every day.”  The two original validation studies of the PHQ-8 totaled 6000 patients 
which demonstrated that the ninth question can be omitted without effect on the validity of the 
questionnaire.59; 60 Of the 198,678 surveyed participants, 17,040 were identified to have a score of 
≥10 indicating a current depressive status.59 Current depression by the PHQ-8 can be defined as 
either as a respondent answering at least 5 of the 8 symptoms to be present “more than half the 
days” (value of 2), or a PHQ-8 score of ≥10 which has an 88% sensitivity and specificity for major 
depression. 60 The PHQ-8 has also been validated for use in cancer cohorts61; 62 to diagnose current 
depressive disorders. Depression is a significant concern in individuals with cancer48 and therefore, 
it is an important measurement to collect so that health care providers may assess and differentiate 
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the depression associated with a diagnosis of cancer and any other situation that may be affecting 
depression levels.  
1.4.2  GAD-7 
Another measurable feature of psychological distress is anxiety. Anxiety disorders are the 
most prevalent class of mental disorders in the general population.63 Although anxiety disorders 
are widely present in the general population, prior to the establishment of the 7-item Generalized 
Anxiety Disorder Scale (GAD-7), there was a dearth of valid screening tools for the diagnosis of 
generalized anxiety disorder.63 Validation of the GAD-7 was performed on more than 5000 
subjects in the general population, affirming validity and internal consistency across age and 
gender.63 It has also been validated in the primary care setting,64 and has been used as a 
measurement for levels of anxiety in patients with cancer.65 The recommended interpretation of 
GAD-7 in clinical settings is of scores of ≥10 as “yellow flags” and GAD-7 scores of ≥15 as “red 
flags” for the presence of anxiety disorders.63 A yellow flag score is associated with a positive 
likelihood ratio for the presence of generalized anxiety disorder of 5.1, whereas a red flag is 
associated with a positive likelihood ratio of 8.7.63 Elevated GAD-7 scores can also be indicative 
of panic disorder, social anxiety disorder, and posttraumatic stress disorder.63  The GAD-7 has a 
range of scores from 0-21, with the 7 questions having response ranges on a Likert scale of 0-3. 
The questionnaire asks respondents to rate the frequency of their emotions corresponding to 
different scenarios over the past two weeks on a Likert scale of 0-3, where 0 is “Not at all”, 1 is 
“several days”, 2 is “more than half the days”, and 3 is “nearly every day.” The GAD-7 has 89% 
sensitivity and 82% specificity for generalized anxiety disorder and can also be used to screen for 
other anxiety disorders: panic disorder (sensitivity 74%, specificity 81%), social anxiety disorder 
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(sensitivity 72%, specificity 80%) and post-traumatic stress disorder (sensitivity 66%, specificity 
81%).66 Anxiety is another main concern in individuals with cancer 48through measurement of 
anxiety over time such instruments as the GAD-7 allow for the differentiation of anxiety from 
cancer diagnosis and other situations under investigation. 
1.4.3  IES-R 
The Impact of Event Scale- Revised (IES-R) is a measurement of common symptoms of 
post-traumatic stress disorder (PTSD) and the impact of stressful life events within the previous 
seven-days.67 The IES-R is a 22-item scale with three subscales to measure: avoidance behavior, 
intrusive thinking related to the event, and emotional arousal.67 These three subscales represent the 
DSM criteria for PTSD.51 The questionnaire can be adjusted to include reference to a specific 
traumatic event. The subject is asked to indicate frequency of the event on a five point scale (0 
“not at all” to 4 “extremely”) over the past 7 days.68; 69 Total scores of the IES-R above 25 represent 
high risk of PTSD.69 The IES-R yields a total score ranging from 0-88 and subscale scores 
calculated for intrusion, avoidance, and hyperarousal. The avoidance subscale looks at instances 
of individuals experiencing denial or inhibition of conscious awareness of traumatic emotions.68 
Intrusion symptoms report on persistently experienced memories, nightmare, flashbacks, distress 
or reactivity to reminds of the trauma. Hyperarousal report on trauma-related arousal or reactivity 
that either began or worsened after the trauma through irritability, changes in behavior, heightened 
reactions, or difficulty sleeping or concentrating.70 In general, the IES-R is not used to diagnose 
PTSD, but rather has been shown to provide a preliminary diagnosis. This scale provides a self-
reported measurement of patient perception of trauma resulting from their diagnosis of cancer. As 
an instrument, the IES-R encompasses the remaining two common features of psychological 
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distress in cancer: fear and discouragement. The impact from the diagnosis of cancer can be 
compared over time and monitored against genetic counseling and genetic testing.   
1.4.4  MICRA 
The Multidimensional Impact of Cancer Risk Assessment (MICRA) is a validated 
questionnaire used to measure the impact of result disclosure following genetic testing within the 
past week.71 The MICRA questionnaire is a 25-item scale which supports 3 subscales: Distress (6 
items), Uncertainty (9 items), and Positive Experiences (4 items). In MICRA the scores are allotted 
values of 0 (never), 1 (rarely), 3 (sometimes), and 5 (often). The Positive Experiences subscale is 
scored in reverse value order to account for positive interactions.  In a study of 159 female 
participants with various positive or negative genetic testing results,71 all 3 MICRA subscales were 
found to identify subgroups of vulnerable testing participants. Reponses following genetic testing 
were significant for the identification of risk status, decision making, and personal thoughts of 
self-empowerment.72 This questionnaire elicits concerns specifically regarding the genetic testing 
process, results obtained, and patients’ understanding of further management. It is unique in its 
ability to compare those who test positive for cancer-related gene mutations, to those who test 
negative as its responses are directly related to genetic testing outcomes.73 MICRA provides the 
opportunity to compare differences in psychosocial experiences of the different clinical 
subgroups.73 A limitation of MICRA is that it has been validated in women in respect to hereditary 
breast and ovarian cancer, but has yet to be largely used in other hereditary cancer types and that 
it cannot be compared to outside distress testing measurements.73 
In a 2015 study of psychological distress based solely on women with ovarian cancer, 4 
groups were selected to represent a continuum of cancer risk from demonstrated BRCA carriers to 
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women without a family history of breast or ovarian cancer.74 Bjørnslett et al. was the first to 
define a high general MICRA score, identifying it as +1 standard deviation above the mean.74 The 
study also implemented the IES questionnaire demonstrating internal consistency between the two 
measurements.74 Of interest, the study identified that there was no statistical significance between 
mean group scores or total MICRA scores when compared across multiple variables including: 
time from diagnosis, receiving the test result, or duration from taking the result to the disclosure 
of test result to time of the survey. Thus, results supported the view that genetic test results and the 
testing process are of specific and long-term concern for individuals.74   
The utilization of the MICRA questionnaire allows for further differentiation of 
psychological distress based on genetic test result. While genetic testing results are not an indicator 
of genetic counseling efficacy, they do represent a source of potential distress.44; 45 UTS is not a 
diagnostic test method, thus it is important that research work include potential distress associated 
with the testing process and final results. Individuals with positive abnormal screening results may 
be referred to genetic counseling for germline testing without any family history of cancer. It is 
important to measure the uptake of management recommendations that have been made based on 
genetic test results whether positive or negative, especially in these individuals where prior to 
referral to genetic counseling, it is largely possible that LS was a previously unknown condition. 
MICRA supports scales of uncertainty, distress, and positive experiences which are all important 
factors in the continued utilization of genetic counseling and testing following abnormal UTS 
results.   
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2.0 Introduction 
Current practices in oncology involve collection of tumor tissue in an effort to better 
understand the disease process for appropriate targeted treatment methods. One aspect of these 
pathological analyses involves the identification of tumor specific markers such as the presence of 
microsatellite instability, or DNA mismatch repair (MMR) protein deficiency.7; 9 Inherited 
pathogenic variants in the DNA mismatch repair genes are associated with Lynch Syndrome 
(LS).7; 9 The loss of these proteins in solid tumor testing may be indicative of a corresponding 
germline pathogenic variant. The use of tumor studies in colorectal cancer (CRC) has been found 
to detect >90% of LS patients.7; 9 Universal tumor screening (UTS) and the recent shift in 
availability of next-generation sequencing has resulted in a significant number of patients being 
identified as having LS whose personal and family histories may lack the traditional clinical 
features of Lynch syndrome.7; 8 In 2009, the Evaluation of Genomic Applications in Practice and 
Prevention (EGAPP) working group made the recommendation of universal testing for all patients 
newly diagnosed with CRC, through microsatellite instability (MSI) and immunohistochemistry 
(IHC) staining for MMR protein expression.10 This method has been acknowledged as cost-
effective and beneficial to patients, resulting in a reduction of morbidity and mortality.10  
LS predisposes individuals to increased risks of several types of cancer, the highest of 
which is CRC.5 The lifetime-risk for colorectal cancer in individuals with LS may be as high as 
70%.5 Due to the quantification of these cancer risks, prevention and management guidelines have 
been established to reduce the mortality rate of those with LS. LS is known to be caused by 
mutations in one of five genes related to MMR: MLH1, PMS2, MSH2, MSH6, and EPCAM. 
Research has demonstrated that Lynch-related cancers display a specific histologic pathology that 
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has allowed the development of therapeutics that are most effective against these pathologies.6; 19-
21 Specifically, finding a somatic loss of MLH1, PMS2, MSH2, or MSH6 proteins through tumor 
screening provides a method to subsequently identify individuals at risk for a corresponding 
germline variant in these genes.7; 9 The identification of LS has implications beyond therapeutic 
care; it can also initiate cascade screening of related family members, prompting early intervention 
services and decreasing Lynch-related cancer mortality.  
Although there are individual and familial implications related to the identification of a LS 
associated pathogenic variant, there is limited research regarding patient perspectives of universal 
tumor screening in Lynch Syndrome.22; 34-37 Of the literature that is currently available for LS, it 
has thus far concluded an overall positive attitude toward tumor screening for CRC patients, but 
has provided limited perspective on the impact of this testing on patient mental health and 
anxiety.36 This is an important area of research as psychological distress has been associated with 
genetic testing results58 and is already a concern in patients diagnosed with any type of cancer. 
However, the majority of research regarding patient perspectives of genetic testing has been 
completed in the realm of Hereditary Breast and Ovarian Cancer syndromes38; 39Voorwinden et al. 
identified that as much as 10-20% of patients with a positive diagnosis of BRCA1/2 mutation had 
negative psychological impacts following the result.58 In general, patients with a diagnosis of 
cancer are at risk for the development of multiple psychological concerns including: depression, 
anxiety, fear, and feeling discouraged.48 Psychological distress may be further complicated by the 
receipt of UTS results.  
As a screen, the results of the UTS are not diagnostic. Moreover, germline testing may not 
identify an underlying pathogenic variant and leave patients with ambiguity in the interpretation 
of their genetic test results. Research has yet to elucidate whether there is any incongruence 
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between patient understanding of the implications of somatic variation versus germline variants. 
Given the recent surge in CRC tumor testing, it is important that patient perspectives and anxiety 
levels related to germline testing be considered in their management and treatment plan, including 
in the genetic counseling and testing process. 
In a study of 414 individuals who received UTS, three-quarters (74%) wanted to receive 
their preliminary UTS results, while 26% did not wish to learn these results.47 The disinterest in a 
quarter of the participants in learning their UTS result offers insight into UTS as a potentially 
distressing concept for some individuals. Within this same cohort, upon offering germline testing 
for the participants who received an abnormal UTS result, only 25-33% were interested in 
undergoing germline testing.47 The rationale for the disinterest in receiving genetic results was 
proposed to be related to the stigma associated with genetic testing, while the UTS was considered 
more of a triage test and not a genetic test result since it still required follow-up diagnostic testing.47 
This same study similarly demonstrated that through the utilization of genetic counseling there 
was a reduction in patient distress (levels of depression and anxiety) in patients before and after 
counseling.42 This suggests that genetic counseling may be associated with changes in patient 
distress related to UTS.   
In summary, as a pilot study, this project has two specific aims: 
(a) To investigate the role of genetic counseling in the variation of patient distress
levels over time.
(b) To compare distress levels in patients with CRC and abnormal tumor study
results to patients without abnormal tumor study results.
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A case-control model was used to measure levels of patient distress over time, with the aim to 
assess the impact of UTS on patients’ levels of distress, and the potential impact of genetic 
counseling and germline testing on these levels of distress. 
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3.0 Methods 
3.1 Participants 
In an attempt to better understand the impact of both abnormal UTS results and genetic 
counseling, we recruited three separate cancer patient groups. The first group included patients 
who were referred to the UPMC Hereditary Gastrointestinal (GI) Tumor Program for hereditary 
cancer risk assessment based on MMR deficiency identified in CRC on pathologic analysis. The 
second group was comprised of patients referred to the Hereditary GI Tumor program at UPMC 
who received genetic counseling for a personal history of CRC diagnosed prior to the age of 50 
and who had normal UTS results (MSS tumor or intact MMR protein expression). The final group 
of patients, recruited through the UPMC Surgical Oncology department, was diagnosed with CRC 
after age 50 and had normal UTS results. Approval for the study was provided by the University 
of Pittsburgh Institutional Review Board (PRO18040719) (Appendix A.7).    
3.2 Eligibility Criteria 
Different eligibility criteria were defined for each patient group. Participants were eligible 
for the first group (hereafter referred to as the case group) if they had abnormal tumor testing 
results indicating a loss of any of MSH2, MSH6, MLH1, or PMS2, regardless of age. For those 
identified to have a MLH1 or PMS2 protein loss, participants were excluded if BRAF V600E or 
MLH1 promoter hypermethylation was identified on pathology prior to the appointment. 
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Participants in the second group (hereafter referred to as the genetics control group) were identified 
upon referral to the UPMC GI Hereditary Tumor Program as eligible for participation if they had 
been diagnosed with MSS CRC prior to the age of 50. The third group (hereafter referred to as 
cancer control group) was eligible for participation if they had MSS CRC diagnosed after age 50. 
Potential cancer control group participants were excluded if they had previously received genetic 
counseling for hereditary cancers.  
3.3 Recruitment 
Participants in the case group and the genetics control group were approached about the 
study at the beginning of their genetics appointment. Participants in the cancer control group were 
approached directly before their appointments with their surgical oncologist. For those participants 
who expressed an interest in enrolling in the research study, informed consent was obtained, any 
questions were answered, and the investigator then administered the questionnaires.  
3.4 Instruments 
In this study, multiple instruments were used in effort to obtain an accurate assessment of 
the overall level of patient distress. The Patient Health Questionaire-8 (PHQ-8), Generalized 
Anxiety Disorder-7 (GAD-7), and Impact of Event Scale-Revised (IES-R) were used to measure 
patients’ level of depression, anxiety, and cancer-related distress respectively. The MICRA 
questionnaire was also used to measure patient perceptions of distress associated with their 
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germline genetic test results in the participants for the case group and the genetics control group. 
All four of these instruments are validated questionnaires. Questionnaires were administered orally 
at all time points.     
3.4.1  PHQ-8 
3.4.1.1 Instrument 
The eight-item Patient Health Questionnaire (PHQ-8) depression scale is used as a 
validated diagnostic measure for depressive disorders and has clinical utility in comparing levels 
of depression overtime. The PHQ-8 was created as a tool for screening individuals to better assess 
their current psychological state.55; 56 The PHQ-8 consists of eight questions based on DSM-IV 
depressive disorder criteria. The PHQ-8 may also contain a final question assessing risk of suicide 
or self-harm. For the purpose of this study, this question was omitted as it has not been found to 
impact the validity of the questionnaire and was not required for the aims of the study.53; 54  
3.4.1.2 Scoring 
Participants are asked to provide answers to the 8 questions based on their experiences 
within the last two weeks, and answers are ranked using a Likert scale of “Not at all” to “nearly 
every day”. The answers were scored with “Not at all” being zero points, “several days” as one 
point, “more than half the days” as two points, and “Nearly every day” as three points. The points 
from each of the eight answers were then tallied for a total score, with a highest possible score of 
24 points. Any score equal to or above 10 points is considered a diagnosis of depressive disorder.54 
The PHQ-8 scores were measured at all time points for all groups, and the differences were used 
in paired analysis.  
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3.4.2  GAD-7 
3.4.2.1 Instrument 
The seven-item Generalized Anxiety Disorder (GAD-7) tool was utilized to measure 
generalized anxiety disorder as well as utility in comparing anxiety levels over time, in the 
participant cohorts. This questionnaire may indicate diagnoses of generalized anxiety disorder, 
panic disorder, social anxiety disorder, and posttraumatic stress disorder.57 It has been validated in 
multiple large-scale reviews, including populations of individuals with cancer.59 For the purpose 
of this study, the GAD-7 was used as a measurement of generalized anxiety disorder.  
3.4.2.2 Scoring 
Total scores for the GAD-7 range from 0-21. A Likert scale is used in this questionnaire 
and participants are asked to assess their corresponding value for how often they have been 
bothered over the past two weeks. The scale employs the same range as is seen in the PHQ-8 using 
a scale from 0-3 with zero corresponding to “Not at all” and three corresponding to “nearly every 
day.” Totals were tallied across the seven possible questions with a score ≥15 representing a 
clinical diagnosis of anxiety. The GAD-7 was provided to participants at all three time points and 
was compared across all time points to determine differences in generalized anxiety levels over 
time.  
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3.4.3  IES-R 
3.4.3.1 Instrument 
The Impact of Event Scale-Revised (IES-R) was used to measure the impact of trauma 
specifically pertaining to the participant’s cancer diagnosis within the past week.61 This 22-item 
scale contains three subdomains: avoidance behavior, intrusive thinking related to the event, and 
emotional/hyper-arousal. The three subdomains are representative of the clinical DSM criteria in 
the diagnosis of post-traumatic stress disorder (PTSD).45 The IES-R is not a diagnostic tool for 
PTSD but acts as a preliminary screen for those at risk for PTSD from a traumatic event. The 
questionnaire was adjusted to ask for their responses over the past week as related to their “most 
recent cancer diagnosis.” The date of the diagnosis was not always included as exact dates were 
not always available.  
3.4.3.2 Scoring 
The total score for the IES-R can range from 0-88. Subdomain scores can be calculated 
separately. The totals for avoidance and intrusion can range from 0-32 (based on eight questions 
being included in each), while the total for hyperarousal can range from 0-24 (based on the 
inclusion of six questions regarding hyperarousal). As with the PHQ-8 and GAD-7, the IES-R was 
measured at all three time points and both the subdomain and total scores were compared across 
participants over time. Cut-points for the IES-R have been widely discussed, for this study, we 
have utilized a cut-point of ≥25 as has been presented in various other studies to demonstrate a 
“high-risk” of an individual with PTSD.75; 76 
 29 
3.4.4  MICRA 
3.4.4.1 Instrument 
The Multidimensional Impact of Cancer Risk Assessment (MICRA) is a more recently 
developed, validated questionnaire that can be used as a method to measure the impact of result 
disclosure following genetic testing.65 The MICRA questionnaire is comprised of three 
subdomains: distress, uncertainty, and positive experiences. This questionnaire was developed to 
assess concerns regarding: the genetic testing process, the results obtained (positive, negative, 
variant of uncertain significance), and patients’ understanding of any available management 
guidelines. The use of the MICRA questionnaires allows for comparison between groups and 
individuals who have received genetic testing based on the results of their testing.  
3.4.4.2 Scoring 
MICRA consists of 25 questions that participants are asked to answer based on their 
feelings within the past week. There are four responses for each question: never, rarely, sometimes, 
or often. The answers are allotted values of zero, one, three, and five respectively. The potential 
total of each subdomain varies. For the distress domain, there are 6 items included, so the highest 
possible score is 30 points. The uncertainty domain consists of 9 items, with highest possible score 
being 45 points. Conversely, the positive experiences domain consists of 4 items, but is reverse 
scored. As such, for positive experience, an answer of “never” corresponds with a value of 5, 
whereas an answer of “often” would be given a value of 0. The total possible value for positive 
experiences would be 20, with a higher total value corresponding with a lower positive experience. 
A high MICRA score is identified as being over one standard deviation above the mean.68 The 
MICRA questionnaire was given only at the final time point, two weeks following the receipt of 
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genetic test results from genetic counselors, and thus was provided only to the case group and the 
genetics control group.  
3.5 Study Protocol 
The research investigators involved in this study included genetic counselors, a 
gastroenterologist, a surgical oncologist, and two genetic counseling students who facilitated the 
study enrollment and administration of follow-up questionnaires (Figure 1).  
During the first study time point (Figure 1), patients provided informed consent, three 
questionnaires (PHQ, GAD-7, and IES-R) were orally administered to the patient, and the results 
were collected by the research investigator. The questionnaire was given in the presence of any 
other individuals attending the appointment with the participant. During the appointment, the 
participant received individualized genetic counseling by a certified, licensed genetic counselor, 
and was then seen by a physician for a complete consult.  
The genetic counseling appointment consisted of a one-hour session. During this session, 
participants in the case and genetics control groups received genetic education and information 
pertaining to their risk of Lynch syndrome. They were provided with personalized risk assessment 
based on medical and family history and they received psychosocial counseling when appropriate. 
Visual aids were used throughout the session to support patient understanding.  
Consented participants were contacted via telephone two weeks after their enrollment, 
before notification of their genetic test results. At this second time point, they were asked to 
complete the PHQ-8, GAD-7, and IES-R questionnaires again. If patients were not reached on the 
two-week mark, they were called until they were reached. If they could not be reached prior to the 
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availability of their test results, then they were excluded from the second time point, and were 
attempted to be reached for the third point.  
Genetic test results were disclosed by the genetic counselors over the telephone. The 
participants were then contacted two-weeks after their results were disclosed. In instances where 
further genetic testing was required after the original test was completed, participants were not 
contacted until two weeks after the final testing results had been disclosed. All individuals in the 
case group and the genetics control group decided to undergo genetic testing. Patients were 
subsequently sent a letter outlining their results and management recommendations for themselves 
and their family. When patients were contacted over the telephone at the third time point, they 
were again asked to complete the PHQ-8, GAD-7, and IES-R, with the addition of the MICRA 
questionnaire for the case and genetics control groups. At that point participants were told they 
had reached the end of the study.  
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Figure 1 Protocol Flowsheet 
3.6 Data Analysis 
The data from each of the questionnaires were assessed for normality of distribution in 
total. For the measures which included multiple subscales, all domains were assessed for 
normality. Both, paired t-tests and non-parametric Wilcoxon ranked sign tests, were performed to 
determine mean differences in scores across all three time points (Appendix B). The statistical 
program STATA (Stata Corp 2015) was used to perform relevant analyses. The threshold for 
significance was set at p<0.05 at a 95% Confidence Interval. Given the small sample size (n=23) 
observed qualitative trends were also reported. 
33 
4.0 Results 
Participants were recruited between July 2018 and January 2019 and a total of 23 
participants were enrolled. Each participant was followed for at least four weeks following 
recruitment. One of the case participants was lost-to-follow up, but this participant’s baseline data 
was still incorporated in data analysis. Two of the genetics control participants did not have a 
measurement at the second time point as the results were returned before the participants were 
reached for their second measurements. For these individuals the second time point was skipped, 
and the third time was administered two weeks post results disclosure. A total of 10 participants 
were recruited in the case group, and a total of 9 participants were recruited in the genetics control 
group. Due to constraints related to patient recruitment, a total of 4 patients were identified in the 
sporadic control group. One participant in the sporadic control group did not have a third time 
point collected as he was lost to follow up before the submission of this thesis. All participants had 
a diagnosis of either colon or rectal cancer. Additionally, while adherence to time point scheduling 
of two weeks between administration was attempted, given various testing methods and laboratory 
use for genetic testing, there was variability in the length of time between the test measurements.  
4.1 Demographics 
A total of 23 participants were enrolled in this pilot study. Of those enrolled, 30.4% were 
female, and all of the participants identified as white. Participant ages ranged from 22-89 years 
within the groups with a total mean age of diagnosis between the groups of 51.1 years. The 
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sporadic control group consisted entirely of male participants with age at diagnosis ranging 
between 52-59 years old, and an average time since diagnosis of 17.75 months. Of the genetics 
control group, the mean age at diagnosis was 39.1 years (range 22-49) and the average time in 
months since diagnosis was 73.6 months (approximately 6 years, range 1-297 months). The case 
group had a mean age of diagnosis of 60.5 years (range 39-86) and an average time since diagnosis 
of 5.8 months (range 0-12 months) (Table 1). All participants (100%) in the genetics control and 
the case groups met NCCN 2018 guideline criteria for genetic testing; none of the sporadic control 
participants met NCCN based on personal history alone or tumor testing as all were MSS.  
Table 1 Demographics 
Group Case Genetics Control Sporadic Control Total 
n=10 n=9 n=4 n=23 
Age (years) 
Mean 60.9 45.2 56.5 54.2 
Range 39-87 26-57 53-59 26-87
Sex 
Female (n) 40% (4) 33.3% (3) 0% (0) 30.4% (7) 
Male (n) 60% (6) 66.7% (6) 100% (4) 69.6% (16) 
Ethnicity 
White 10 9 4 23 
Other 0 0 0 0 
Age at Diagnosis (years) 
Mean 60.5 39.1 54.5 51.1 
Range 39-86 22-49 52-59 22-86
Time Since Diagnosis (months) 
Mean 5.8 73.6 17.75 34.4 
Range 0-12 1-297* 7-31 0-297
*297 months = 24.75 years
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4.2 Baseline Distress Measurements Across All Participants 
Baseline measurements (PHQ8, GAD-7, IES-R) demonstrated distress across groups 
(Table 2). Although no statistically significant differences between case and control scores were 
identified, the mean values for all three measurements trended higher in the case group as 
compared to the controls. Clinical significance for the measurements was identified in 3/10 (30%) 
participants in the case group for depression while only one individual in each control groups (11% 
in the genetics control and 25% in the sporadic control) reported a significant level of depression 
at the baseline measurement (Fisher’s Exact p-value=0.582) (Table 4). For all other measurements, 
there was no difference in the number of clinically affected case versus control participants 
(Fisher’s Exact p-values=1.000). The largest difference in mean scores between the case and 
genetics control groups was seen for the IES-R (p-value = 0.3864 95%CI [5.0,17.2]). The values 
for PTSD risk trended higher in the case group with a departure in the median value (11.5 in cases, 
2 and 4 in controls).  
Further investigation into the subscales of the IES-R Measurement between the genetics 
control and case groups found that the largest difference in mean was observed in the intrusion 
subscale (p=0.639 95%CI [2.3,7.2]). The scores for hyperactive thoughts were very similar across 
the two groups and was the lowest values of the IES-R subscales. The case group had a median 
value of 3.5 for the avoidance subscale, while the control group had a median value of 0. The 
ranges were similar across both groups. The highest values for all subscales within the control 
group were from the same individual.  
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Table 2 Baseline Distress Values 
Group Case Genetics Control Sporadic Control Total p-values 
  n=10 n=9 n=4 n=23  
PHQ8           
Mean ± SD 6.9 ± 8.3 3.9 ± 4.8 4.8 ± 1.9 5.4 ± 6.2 0.587 
Median 3 3 5.5 3   
Range 0-22 0-15 2-6 0-22   
Score >10 30% (3) 11.1% (1) 0% (0) 4   
Range >10 14-22 15 - 14-22  
GAD-7           
Mean 4.4 ± 5.7 4.3 ± 5.3 3.8 ± 3.3 4.3 ± 5.0 0.9771 
Median 1.5 2 4 2   
Range 0-15 0-16 0-7 0-16   
Score >15 10% (1) 11.1% (1) 0% (0) 2   
Range >15 16 16 - 16   
IES-R           
Mean 14.5 ± 16.9 8.7 ± 12.8 8 ± 9.4 11.1 ± 14.0 0.6195 
Median 11.5 2 4 3   
Range 0-55 0-36 22-Feb 0-55   
Score >25 10% (1) 11.1% (1) 0% (0) 2   
Range >25 55 39 - 39-55   
 
Table 3 IES-R Subscale Baseline Measurements 
Group Case 
Genetics 
Control Total p-values 
  n=10 n=9 n=19  
INT         
Mean ± SD 6.2 ± 6.3 3.9 ± 5.2 5.1 ± 5.8 0.639 
Median 4.5 1 2   
Range 0-11 0-13 0-13   
AVD         
Mean ± SD 5.5 ± 6.5 2.6 ± 3.7 4.1 ± 5.4 0.65 
Median 3.5 0 2   
Range 0-21 0-10 0-21   
HYP         
Mean ± SD 2.8 ± 4.8 2.3 ± 4.3 2.6 ± 4.5 0.091 
Median 0 0 0   
Range 0-15 0-13 0-15   
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Table 4 PHQ8 Clinical Depression at Baseline by Fisher's Exact 
 Clinical Depression Screen  
Group Negative Positive Total 
Case 7 3 10 
Genetics  8 1 9 
Control        
Total 15 4 19 
  0.2 0.8 1 
    
  Fisher's exact =     0.582 
4.3 Mean Score Trends over Time 
Participant scores for PHQ8, GAD7, and IESR are represented by heat maps (Tables 5,6,7). 
The three time points are represented in the columns. Red cells indicate clinically significant 
scores. Yellow-orange colors represent moderate scores (at least half the score required for clinical 
significance). Green cells indicate low scores, from zero up to moderate scores.  
For the PHQ8 a clinical diagnosis of depression is designated by a score of >10 points. As 
such, the heat map distributes colors from green at 0 points to red >10 points. Some case 
participants demonstrated higher scores for PHQ across time points, including an increase in score 
from the second to the final time point (Table 5). The lowest mean levels of depression-associated 
distress over time is seen across the genetics control group, while sporadic control participants 
demonstrate moderate levels of depression. Most participants tended to approximately maintain 
levels of distress across the three time points.  
The GAD7 scores indicate clinical concern when >15 points. The distribution of GAD7 
scores across case participants demonstrate comparable mean scores when compared to the 
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genetics control group, but the case group did have more participants with levels indicative of 
clinical anxiety (Table 6). This trend is observed qualitatively though the distribution of color but 
can be seen in the value of means between and across groups and time points. While there were 
changes in scores for several participants, similarly, to the PHQ8, overall, individual participants 
tended to generally maintain similar levels of distress across time points.    
For the IES-R, scores are clinically significant when >25. It appeared that overall scores 
tended to decrease between the first and second time points, with the exception of two individuals 
who demonstrated increased scores at the second time point (Table 7).  For individuals in the 
genetics control group who began with clinically significant levels of PTSD, those levels persisted 
overtime. There are three genetics control participants with increased IES-R scores while all other 
participants demonstrate low levels (green) for IES-R scores. No sporadic control participants had 
overall increased IES-R score between the first and third time point.  
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Table 5 Participant PHQ8 Score Heat Map 
 Timepoint 
Participant 
ID Pre GC Post GC Post results 
Cases       
ATS#1 0 0 0 
ATS#3 6 0 1 
ATS#6 22     
ATS#8 0 0 0 
ATS#9 19 9 20 
ATS#12 2 6 8 
ATS#16 0 0 0 
ATS#19 3 3 3 
ATS#21 14 17 16 
ATS#22 3 4 1 
Mean 6.9 4.3 5.4 
Controls       
ATS#2 15 12 9 
ATS#5 0 0 0 
ATS#10 0 0 0 
ATS#11 0 - 0 
ATS#13 3 - 2 
ATS#14 6 5 0 
ATS#15 3 4 4 
ATS#17 2 1 1 
ATS#18 6 2 14 
Mean 3.9 3.4 3.3 
ATS#23 2 9 1 
ATS#26 5 5 5 
ATS#27 6 4 5 
ATS#28 6 7 7 
Mean 4.7 6.3 4.5 
 
  Table 5. Scores are based on a gradient with low scores  (0-4) range from green to orange and moderate scores (5-9) 
from orange to red with clinically relevant scores of ≥10 
indicated in red. 
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Table 6 Participant GAD7 Score Heat Map 
 Timepoint 
Participant ID Pre GC Post GC Post Results 
Cases       
ATS#1 0 0 0 
ATS#3 0 4 1 
ATS#6 9     
ATS#8 0 0 0 
ATS#9 11 7 18 
ATS#12 2 2 4 
ATS#16 0 0 0 
ATS#19 5 3 2 
ATS#21 16 15 15 
ATS#22 1 0 2 
Mean 4.4 3.4 4.7 
Controls       
ATS#2 16 11 14 
ATS#5 0 0 0 
ATS#10 0 0 0 
ATS#11 0 - 1 
ATS#13 2 - 3 
ATS#14 1 0 3 
ATS#15 7 15 12 
ATS#17 6 1 1 
ATS#18 7 5 12 
Mean 4.3 4.6 5.1 
ATS#23 2 11 2 
ATS#26 6 3 3 
ATS#27 7 1 4 
ATS#28 0 0 0 
Mean 3.8 3.8 2.3 
 
  
Table 6. Scores are based on a gradient with low scores  
(0-10) range from green to orange and moderate scores (10-
14) from orange to red with clinically relevant scores of ≥15 
indicated in red. 
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Table 7 Participant IES-R Score Heat Map 
 Timepoint 
Participant ID Pre GC Post GC Post Results 
Cases       
ATS#1 1 0 0 
ATS#3 0 0 0 
ATS#6 24     
ATS#8 0 0 0 
ATS#9 55 56 32 
ATS#12 8 7 5 
ATS#16 3 1 0 
ATS#19 15 7 3 
ATS#21 18 43 37 
ATS#22 21 5 4 
Mean 14.5 13.2 9 
Controls       
ATS#2 36 18 33 
ATS#5 1 0 1 
ATS#10 0 0 0 
ATS#11 0 - 0 
ATS#13 3 - 7 
ATS#14 0 0 0 
ATS#15 18 30 29 
ATS#17 2 0 0 
ATS#18 19 38 59 
Mean 8.8 12.3 14.3 
ATS#23 3 5 2 
ATS#26 22 18 13 
ATS#27 5 0 0 
ATS#28 2 0 0 
Mean 8 5.8 3.8 
 
 
 
Table 7. Scores are based on a gradient with low scores  
(0-13) range from green to orange and moderate scores (13-
24) from orange to red with clinically relevant scores of ≥25 
indicated in red. 
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4.4 Individual Score Changes Across Genetic Counseling Groups 
A summary of participant score changes are reported in Table 8. These changes are based 
on whether the clinical significance of the values reported for each individual changed between 
any given time points. Further interpretation is provided for each assessment for each participant. 
Genetic test results were also listed beside each participant identification. Within the case group a 
total of 4 clinically significant changes were identified, all in different individuals.  
One participant was identified to have a clinically significant change in depression. 
ATS#12 reported no clinical depression at the first two time points with levels indicative of clinical 
depression reported at the final time point after disclosure of a negative genetic test result.  
Two changes were noted in levels of anxiety. For participant ATS#9, their level of anxiety 
was reduced following genetic counseling, and subsequently increased two weeks post result 
disclosure where they received a positive genetic testing result. Alternatively, ATS#19 showed a 
decrease from mild anxiety before GC to levels not clinically significant both after GC and 
following results disclosure.  
One participant had a change in IES-R values that was indicative of an increased risk for 
PTSD. They reported low-risk PTSD results prior to genetic counseling while their score 
subsequently increased to high risk both after genetic counseling and decreased while maintaining 
high-risk status two-weeks post disclosure of a positive genetic testing result.   
The genetics controls similarly exhibited changes in their clinical levels of distress. For the 
control group there were eight clinical changes reported for four individuals. One participant, 
ATS#18 reported clinically significant changes across all three instruments. They were the only 
genetics control to report a clinically significant change in depression with their score increasing 
from not clinically significant to significant post result disclosure of a negative test result. 
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Interestingly, all clinical changes for this participant were increases at the point of assessment after 
result disclosure. Their anxiety level was recorded as mild until results disclosure at which point 
it increased to moderate. Whereas their PTSD risk increased from low to high after genetic 
counseling and increased in score while maintaining high risk after results disclosure.  
Of the four genetics control individuals (4/9, 44.4%) that had clinically significant changes 
in distress scores, all four individuals demonstrated changes in anxiety. Three of the four 
participants demonstrated changes in both anxiety and PTSD. Of the two participants remaining 
that showed changes in both anxiety and PTSD (the third is discussed above), one participant 
(ATS#2) reported an anxiety reduction from severe before GC to moderate both after genetic 
counseling and post results disclosure. While this participants’ risk of PTSD did drop from high 
risk before genetic counseling to low risk after genetic counseling, it increased to high risk again 
following disclosure of negative genetic test results. For the other participant (ATS#15) that 
demonstrated a change in both anxiety and PTSD risk the participant had an increase in anxiety 
from mild before genetic counseling to severe post genetic counseling, with a reduction to 
moderate after disclosure of results. The participant’s PTSD risk scores increased for both time 
points following genetic counseling. The final participant that had a change in anxiety (ATS#17) 
reported mild anxiety before genetic counseling with a decrease to not clinically significant levels 
at both time points following genetic counseling.  
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Table 8 Summary of Changes in Clinical Significance 
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4.5 MICRA Results 
MICRA scores were collected for the case group and the genetics control group at the final 
time point (approximately 2 weeks after receiving genetic testing results). The MICRA 
questionnaire contains three subscales: distress, uncertainty, and positive experience. Participant 
subscale scores are outlined in Table 9 along with their genetic test result. For genetic test results, 
any VUS results or somatic testing results were labelled as negative (-) whereas pathogenic, or 
likely pathogenic germline results were indicated with a positive (+) result. All positive results 
provided patients with a diagnosis of Lynch syndrome.  
In the case group, 50% of participants had a positive genetic test result, and were given a 
diagnosis of Lynch syndrome, whereas none of the genetics control participants had a positive 
germline mutation identified. Between the two groups, MICRA distress scores were similar (p-
value=0.604 95%CI [0.1-1.7]) as were positive experience scores (p-value=0.535 95%CI [1.8-
8.6]). The score for uncertainty was higher in the case group as compared to the control group but 
was not statistically significant (p-value=0.757 95%CI [2.9-9.9]).  
When MICRA scores were divided by result type (positive or negative) there were no 
statistically significant differences observed (Distress p-value=0.575, Uncertainty p-value=0.727, 
Positive Experience p-value=0.591), and no consistent trends were observed between or across 
participants based on their result type.  
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Table 9 Participant MICRA Scores 
Subscale 
Genetic 
Test 
Result 
Participant 
ID Distress Uncertainty Positive Experience 
Cases 
ATS#1 0 3 0 + 
ATS#3 0 0 0 - 
ATS#8 1 12 6 + 
ATS#9 3 21 3 + 
ATS#12 0 8 0 - 
ATS#16 1 5 0 - 
ATS#19 5 22 5 - 
ATS#21 0 4 10 + 
ATS#22 1 8 20 + 
Mean 1.2 9.2 4.9 
Controls 
ATS#2 1 6 0 - 
ATS#5 0 0 8 - 
ATS#10 0 0 20 - 
ATS#11 1 0 2 - 
ATS#13 0 2 5 - 
ATS#14 0 1 10 - 
ATS#15 0 7 0 - 
ATS#17 0 6 0 - 
ATS#18 3 9 0 - 
Mean 0.6 3.4 5 
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5.0 Discussion 
In this pilot-study, genetic counseling was not associated with any specific change in 
psychological distress over time. Previous research in genetic counseling has resulted in increased 
psychological adaptation and patient empowerment, but limited research has been conducted on 
the effect of genetic counseling in situations with abnormal UTS results. 36; 37 In this study, it was 
seen that participants who received genetic counseling for abnormal UTS demonstrated an average 
decrease in psychological distress scores at the second time point for all measurements. When 
looking at clinically significant changes to scores in the group which received genetic counseling, 
there seemed to be fluctuations in the changes depending on the individual at different time points. 
No one trend was identified to account for these fluctuations in clinical significance.  
The majority (77.8%, 7/9) of patients in the genetics control group demonstrated a decrease 
in distress measurements between the first and second time points. One participant in the genetic 
control group indicated that his increased level of distress at the second time point was related to 
waiting for the results from a recent scan, separate from the genetic testing. Of note, the mean 
distress levels in case participants were lower at the second time point when compared to genetics 
controls but did increase at the third time point.  
When looking at clinically significant changes in the genetics control population, 44.4% of 
patients (4/9) demonstrated some sort of clinically significant change in their scores. Three of these 
four (3/4) individuals reported increased clinical levels of the measurements between the time 
point before genetic counseling and the time point post results disclosure. Only one genetics 
control participant (1/9, 11.1%) reported a decrease in anxiety between the first time point before 
genetic counseling and the final time point following results disclosure. The genetics control 
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participants also had a larger time since diagnosis as compared to the case group. These 
fluctuations in clinical significance may be due to the resurgence of thought surrounding their 
previous cancer diagnoses and the increased awareness of potential future diagnoses. Whereas the 
case patients were all recently diagnosed within the last year, and their maintained clinical levels 
of distress may be consistent with an ongoing, active diagnosis of cancer.  
The two case patients (20%, 2/10) that reported clinical changes to anxiety exhibited a 
decreased level of anxiety following genetic counseling. The participant that tested positive for a 
pathogenic variant indicated an increased level of anxiety following that result, which is consistent 
with the literature which suggest positive genetic test results may increase anxiety in some 
individuals. For the participant (ATS#21) that exhibited a change in risk of PTSD, they reported 
higher risk of PTSD following genetic counseling. Yet, genetic counseling did not seem to have 
an effect on the case participant that had a clinical change in depression score. Participant ATS#12 
exhibited an increase to clinically significant levels of depression following disclosure of a 
negative genetic test result. The fluctuations and inconsistency between the reported clinical 
changes in the case patients would have been better supported if it had been possible to recruit a 
larger number of sporadic case controls. This would have allowed for comparison between the 
fluctuation of distress levels in participants with more recent cancer diagnoses to better discern the 
impact of genetic testing from that of active cancer treatment and management. The interpretation 
of these results is greatly limited by the sample size, yet the data does present data suggesting that 
further investigation is warranted to better understand any patterns between genetic counseling and 
abnormal UTS results.   
The MICRA questionnaire was employed for the case and genetics control groups and the 
results were recorded in Table 9. No differences in means across the samples were statistically 
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significant. Given the small sample size present in this pilot study the lack of statistical significance 
is not surprising, yet it did appear that there did not seem to be distress associated with the genetic 
test results as more than half (10/19, 52.6%) of participants reported a score of 0 for distress. 
However, when looking at the scores for uncertainty (Table 9) following the report of genetic test 
results, only 1/10 (1%) of the case participants reported a score of 0, while 3/9 (33.3%) of genetics 
controls reported a score of 0. Again, no statistical significance was identified between these case 
and control groups for uncertainty (p-value=0.757), however the mean of the case group was 
reportedly higher for uncertainty than the control group (9.2 as compared to 3.4 respectively). 
Across both groups there was no statistical significance associated with a positive versus a negative 
result and the score of uncertainty (p-value=0.727). Similarly, no qualitative trend is identified 
across uncertainty scores depending on result type as both positive and negative cases each report 
increased and lower scores of uncertainty. Although these results are not statistically significant, 
they do merit further investigation in larger populations.  
A potential explanation for the uncertainty in individuals who tested positive for 
pathogenic variants is that there is an increased concern for other family members’ similarly having 
a hereditary predisposition, and the uncertainty associated with family members testing outcomes 
as well as their own future cancer risks. A potential hypothesis for the change in individuals who 
tested negative may be related to the uncertainty in the interpretation of the residual risk following 
a negative germline result with an abnormal UTS. This is particularly possible considering the 
results of the MICRA demonstrated increased levels of uncertainty in the case group regardless of 
germline testing result. Ultimately, this presents a potential area of further research into the reasons 
for which individuals might have increased levels of perceived psychological distress after 
receiving results of genetic testing following abnormal UTS. Changes in scores across all 
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participants were not statistically significant, yet, given the small number of participants included 
in this study, observed trends may still suggest meaningful impact from genetic counseling on 
psychological distress, adding to the existing work suggesting value in the impact of genetic 
counseling.36-38; 44; 56; 73 
Contrary to previous research indicating the impact of results on individuals’ quality of 
life,34 47 the  genetic testing result did not appear to impact distress levels of individuals at the final 
time point. Interestingly, there were no participants in the genetics control group that were 
identified to have a positive germline mutation which is not consistent with the current thought 
that approximately 8% of individuals with MSS CRC diagnosed before age 50 have an actionable 
pathogenic variant identified through multigene panel testing.5 Regardless of result type (positive 
or negative) case participants seemed to express increased levels of uncertainty as compared to the 
genetics control group, which is again inconsistent with previous research.74  This identifies a 
potential area of increased concern with UTS, although acknowledges that further investigation in 
large cohort sizes is required.  
Although this study was unable to identify a significant difference in distress associated 
with result type, there was an increased level of uncertainty which while not statistically significant 
may be of interest for further research. MICRA questions which indicate uncertainty include 
questions surrounding the patient’s interpretation of risk associated with the genetic test results, as 
well as the understanding of individual management guidelines and risk for family members 
(Appendix B). This same uncertainty and ambiguity associated with follow-up germline testing 
was noted in Lindor et al.47 as a difficulty of UTS, and as a potential barrier to further access.  The 
level of uncertainty similarly represents a potential area for investigation in future research with 
larger patient cohorts.  
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When considering the variation in uncertainty, one consideration that can be made is 
whether there is a more appropriate testing approach for these patients, such as paired tumor-
germline testing. As this test type includes somatic as well as germline results it may provide more 
information for patients with the possibility of a somatic answer when a germline is not available. 
Two participants in the case groups underwent paired tumor testing (ATS#6 and ATS#16). 
Unfortunately, ATS#6 was lost to follow up and ATS#16 had two somatic mutations associated 
with their tumor loss as well as a VUS in an unrelated Lynch gene. Participant ATS#16 is currently 
waiting for results associated with the VUS through functional RNA testing, but as an explanation 
for the abnormal UTS result was identified the third timepoint was evaluated 2 weeks after return 
of the paired-testing results. All other participants in the case group received either single gene 
testing (followed by hypermethylation if PMS2 or MLH1 associated) or gene panels. All 
participants in the genetics control group received testing via gene panels. With further research, 
governing bodies such as the NCCN may be able to establish standardizes stepwise testing 
guidelines for these patients. Paired testing represents an important area of further research that 
may contribute knowledge to developing guidelines that target these patients. As studies have 
identified that a major concern of patients following UTS is the cost of genetic testing 41; 42, changes 
in guidelines may lead to an increase in insurance coverage for paired genetic testing, or any other 
relevant testing methodology, ultimately providing more information to patients in the 
interpretation of results with hopes of decreasing patient uncertainty.   
In addition to the consideration of further research to identify a more systematic testing 
approach, this research also illuminates an area of further genetic counseling research. This study 
showed that when presenting for genetic counseling, individuals with abnormal tumor screening 
results may have higher levels of psychological distress (including depression) as compared to 
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patients referred for a personal history of an early-onset cancer, or a family history of cancer, 
although in this study differences were not to a statistically significant level. An important 
consideration in the interpretation of psychological distress between case and controls groups 
within this study is the time since diagnosis. As many individuals in the genetics control group had 
been diagnosed more than one year prior, the diagnosis of cancer was more recent for case 
participants. Several participants in the control group indicated anecdotally that had the study been 
conducted at the time of their diagnoses they would have had increased psychological distress 
levels. Considering that there was a large discrepancy between the cases and the genetics control 
in their time since diagnosis, it is a considerable limitation in this study as we are unable to 
disentangle differences in score based on time since diagnosis, or UTS results.  
Genetic counseling research may be helpful in developing targeted counseling for this 
patient sample. This could include investigation of different counseling styles such as increased 
focus on somatic tumor loss in the pre-counseling session, or an in-person result disclosure rather 
than over the phone to better explain the nuances with the interpretation of germline testing with 
somatic results. As reported in this study, no consistent pattern of distress change was identified 
following genetic counseling. Further research could possibly uncover whether these or any other 
approaches assist in improving the understanding of genetic test results and the impact of genetic 
counseling on psychological distress.  
5.1 Study Limitations and Future Research 
The preliminary results outlined in this pilot study merit additional research. Further 
investigation using large sample sizes may provide more robust evidence regarding the impact of 
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UTS and genetic testing on patient distress levels. Larger sample sizes would also allow for risk 
stratification based on additional confounding variables.  
As a pilot study, the conclusions are greatly limited by the number of participants in this 
study cohort. Original study design had intended to match case participants to sporadic cancer 
controls. The matching was to be based on: cancer type, stage, sex, age (±5 years), and time since 
diagnosis (>1 year or <1 year). Due to the limited patient sample in the available enrollment clinics 
at UPMC, it was not possible to match participants based on these criteria. Even with less 
restriction on matching criteria, only six sporadic control patients were identified. Of those six, 
two candidates refused enrolment, leaving four available for analysis.  
Another limitation is that the data collection at time point one was done in the presence of 
any other individual in the room. There is some evidence to suggest that participants may report 
socially desirable traits rather than true traits. As such, further research may wish to conduct 
interviews in private with participants to control for this bias.  
Some participants had trouble interpreting what the questionnaire was asking or 
misinterpreted the scoring system. One case participant answered “never” on the MICRA 
questionnaire for positive experiences because it was “never a concern,” but that relayed a score 
that was actually negatively associated with positive experiences. Another consideration was that 
there was some difficulty with the administration of the IES-R as the time since diagnosis of 
participants largely varied. Some individuals had many years since their original diagnosis of 
cancer and expressed that had the questions been asked closer to diagnosis they would have 
responded differently. While the ability to measure psychological distress is important, the 
measurement tools utilized were limited. All measurements utilized in this study were previously 
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externally validated but are largely self-administered by participants. Ultimately, the pilot study 
did not have enough participants to confirm these conclusions given the lack of power.  
All analysis was conducted with non-parametric testing analysis given the non-normal 
distribution of data. Due to the small sample size, the use of non-parametric analyses reduces the 
power of the results. The interpretation in the lack of statistically significant results is therefore 
limited as it is difficult to conclude if any differences represent meaningful patterns that could be 
extrapolated to larger populations. 
Participants whose results came back before they could be re-contacted for follow-up at 
the second time point represented a limitation of this study. Given the importance of receiving 
genetic testing results, participants were contacted when results came in, as appropriate in any 
other genetic counseling scenario. As such, this limited the ability to collect time point two data. 
Some participants’ genetic testing required reflexing to other testing options, and therefore did not 
have a consistent time between points two and three.  
Further investigation into patient understanding of UTS and implications after negative 
genetic testing may also be an avenue of potential research. Given the uncertainty levels present 
in the individuals who received germline genetic testing after abnormal UTS, the identification of 
educational resources or development of counseling guidelines for these patients may be 
warranted. Similarly, it may be relevant to assess the process of testing in these individuals to 
observe any differences in uncertainty for those who received paired-tumor and germline testing, 
versus patients receiving only germline testing as follow-up for UTS. Research may also be 
conducted as to the identification of potential interventions that may decrease patient distress 
throughout the diagnosis and testing processes.  
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Finally, an area of further interest may be in the assessment of distress at baseline 
depending on the level of education given at the time of referral. This may include providing a 
script or educational guidelines for doctors who are reviewing abnormal UTS with patients prior 
to referral to genetic counseling, or promoting initial referral contact to be made through the 
genetic counseling office rather than the surgical provider. It may be relevant to assess whether 
increased patient distress at baseline is solely related to a recent diagnosis of cancer, or the 
uncertainty of their genetic counseling appointment relative to their health. It would also be 
prudent for providers to ensure that counseling and psychological assistance is available after 
diagnosis. These patients have demonstrated clinically significant levels of distress that are 
important to address within their overall care management potentially inviting the incorporation 
of psychological counseling as a first-line treatment for cancer patients.  
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6.0 Conclusion 
This pilot study is the first report that presents preliminary support of psychological distress 
in patients undergoing genetic counseling and testing for abnormal UTS results. No significant 
change in distress was reported from patients who underwent genetic counseling. Given the 
significant constraint of sample size, no observations were statistically significant. The qualitative 
differences seen in levels of distress suggest that UTS may be associated with increased 
psychological distress, and uncertainty after genetic testing, regardless of results. Further 
investigation of larger participant cohorts is warranted to provide more insight as to the full effect 
of UTS on patient distress levels and the impact of genetic counseling.  
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7.0 Relevance to Genetic Counseling and Public Health 
The aim of this pilot study was to investigate the impact of abnormal UTS results on patient 
distress levels and to determine if genetic counseling influenced distress levels. This research is of 
importance to the fields of both public health and genetic counseling. Specifically, this study can 
be contextualized within the three core functions of public health: assessment, policy development, 
and assurance. 
A core function of public health is the assessment of a community’s needs. Research on 
the impact of genetic counseling on distress levels for patients who are receiving genetic 
counseling for UTS is limited. As such, the needs of this community have not been adequately 
assessed. Some previous research has demonstrated that genetic counseling can increase patient 
satisfaction and understanding.36-38; 44; 56; 73 Further research on patient distress levels over time 
after receiving genetic counseling can contribute to the understanding of the role of genetic 
counselors in overall quality of care for these patients. Continuing this type of research can 
contribute to the assessment of the needs of this patient population including an increased 
understanding of the outcomes and impact of genetic counseling on patient health and satisfaction.  
The second core function of public health is policy development. UTS is a public health 
measure that was historically controversial as it was considered by some to be a form of genetic 
testing yet, does not require informed consent by patients. It has been largely established that 
informed consent is not an ethical obligation for UTS as it is considered one part of routine 
pathological analysis for which consent is provided though the surgical consent process. However, 
as a public health initiative it is imperative that both the benefits and potential risks or adverse 
effects of screening tests are examined during the development of public health policies. Thus far, 
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there has been inadequate information as to the perception of patient distress levels in the 
population receiving UTS and thus we cannot accurately assess whether the developed policies are 
addressing the priority health needs in this patient population. For UTS to continue and to be 
implemented in more healthcare organizations as a public health policy, it is important that the 
potential effects of these tests on patients’ mental health is better understood.  
Finally, public health interventions should function to provide a level of assurance to the 
community. This includes the evaluation of resources, the implementation of programs, and 
educating the public. Levels of anxiety, depression, and stress have long been associated with 
cancer diagnoses and are currently considered a comorbidity of many types of cancer.48 In an effort 
to improve overall patient health, it is important to evaluate whether UTS is contributing to or 
exacerbating the level of distress in these patients and whether there is potential to manage 
resources that are currently available, or to implement new programs through which to improve 
the wellbeing of these individuals. As depression is the most common psychological symptom of 
individuals diagnosed with cancer, it has been found to be associated with poorer survival rates 
and decreased immune response. 69 Various studies have determined that psychotherapeutic 
interventions can be effective in the mitigation of the effects of depression on cancer outcomes.69
Therefore, should it be determined that patients who are receiving UTS have increased levels of 
psychological distress, then it may be within the best interest of patients and providers to initiate 
appropriate screening protocols and begin psychotherapeutic intervention as early as possible. 
Similarly, if one is able to identify that these patients are at an increased risk for psychological 
distress, then it may be appropriate to focus on psychosocial aspects of genetic counseling within 
any subsequent genetic counseling sessions.  
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As established, this study is not only well positioned within the discipline of public health 
but also demonstrates relevance to the field of genetic counseling. As a profession genetic 
counseling has strived for patient-centered care and uptake of counseling information.31  This study 
presents novel data in the assessment of genetic counseling utility in the context of patient distress 
associated with abnormal UTS results, cancer diagnoses at young ages, and genetic test results. 
One of the aims of this study was to determine the impact of genetic counseling on distress levels 
in patients. As previously mentioned, the study size was not large enough to find statistically 
significant changes in distress related to genetic counseling, but trends in the data did demonstrate 
some interesting patterns associated with the groups who underwent genetic counseling. One such 
trend was that patients in the case group demonstrated a decreased mean distress level at the second 
time point, but that their values subsequently increased at the third time point. Comparably, the 
participants who underwent germline genetic testing after genetic counseling for abnormal UTS 
demonstrated higher levels of uncertainty following results disclosure as compared to those 
individuals who had received genetic counseling and testing based on diagnosis of CRC before the 
age of 50. This finding is relevant to genetic counseling as it appears that genetic counseling did 
provide a decrease in patient distress levels, but that potential uncertainty regarding the results was 
contributing to increased distress at the final time point. It provides a starting point for future 
genetic counseling research to assess the reasons behind individuals’ uncertainty post result 
disclosure. It may lead to identification of a more systematic testing strategy, or the development 
of a specific educational framework for discussion of UTS results in the context of germline 
testing.  
This study identified trends associated with increased levels of depression at the baseline 
in participants who received abnormal UTS results. While this study is limited by the number of 
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participants included, it outlines a potential concern for public health services within the three core 
functions of public health: assessment, policy development, and assurance. It represents and 
encourages assessment of patients receiving UTS and advocates for the continued evaluation of 
the UTS policy as it is currently development. Furthermore, continued study in this area may be 
able to provide assurance through the implementation and management of resources available to 
these individuals including but not limited to the potential consideration for increased intervention 
for psychological wellbeing in these individuals receiving abnormal UTS results. Similarly, this 
study contributes relevant data to the field of genetic counseling in hopes of encouraging continued 
assessment of patient distress levels in this patient population. As scores for psychological distress 
for those who had abnormal UTS results decreased directly after genetic counseling, further studies 
may lead to recommendations for providers and genetic counselors including increased upfront 
discussion and education as to the results and risks of their UTS results.  In conclusion, this study 
represents an important facet of public health and encourages continued research in the definition 
of the impact of psychological distress in these patients within the realm of public health.  
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Appendix A Documentation for Methodology 
This appendix includes all instruments used for measurements, participant data documents, 
the applicable consent form, and the IRB study approval letter.  
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A.1 PHQ-8 Measure 
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A.2 GAD-7 Measure
65 
A.3 IES-R Measure
66 
A.4 MICRA Measure
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A.5 Participant Data Documents 
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A.6 Consent Form 
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A.7 IRB Approval Letter
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Appendix B Data Distribution and STATA Output 
This appendix includes STATA output of histograms and applicable statistical tests. 
72 
B.1 PHQ8 Distribution Graphs and Output
PHQ8 BASELINE DISTRIBUTION BY GROUP 
Group 1= Case participants 
Group 2= Genetics Control Participants 
Group 3= Sporadic Control Participants 
73 
PHQ8 TIMEPOINT 2 DISTRIBUTION BY GROUP 
PHQ8 TIMEPOINT 3 DISTRIBUTION BY GROUP 
74 
PHQ8 ONEWAY ANOVA OUTPUT 
PHQ8 RANK-SUM OUTPUT (GROUP 1 & 2) BETWEEN TIME POINT 1 & 2 
75 
PHQ8 RANK-SUM OUTPUT (GROUP 1 & 2) BETWEEN TIME POINT 1 & 3 
PHQ8 RANK-SUM OUTPUT (GROUP 1 & 2) BETWEEN TIME POINT 2 & 3 
76 
B.2 GAD7 Distribution Graphs and Output
GAD7 BASELINE DISTRIBUTION BY GROUP 
77 
GAD7 TIMEPOINT 2 DISTRIBUTION BY GROUP 
GAD7 TIMEPOINT 3 DISTRIBUTION BY GROUP 
78 
GAD7 ONEWAY ANOVA OUTPUT 
GAD7 RANK-SUM OUTPUT (GROUP 1 & 2) BETWEEN TIMEPOINT 1 & 2 
79 
GAD7 RANK-SUM OUTPUT (GROUP 1 & 2) BETWEEN TIME POINT 1 & 3 
GAD7 RANK-SUM OUTPUT (GROUP 1 & 2) BETWEEN TIME POINT 2 & 3 
80 
B.3 IES-R Distribution Graphs and Output
IES-R BASELINE DISTRIBUTION BY GROUP 
81 
IES-R TIMEPOINT 2 DISTRIBUTION BY GROUP 
IES-R TIMEPOINT 3 DISTRIBUTION BY GROUP 
82 
IES-R ONEWAY ANOVA OUTPUT 
IES-R RANK-SUM OUTPUT (GROUP 1 & 2) BETWEEN TIME POINT 1 & 2 
83 
IES-R RANK-SUM OUTPUT (GROUP 1 & 2) BETWEEN TIME POINT 1 & 3 
IES-R RANK-SUM OUTPUT (GROUP 1 & 2) BETWEEN TIME POINT 2 & 3 
84 
B.4 MICRA Output
MICRA DISTRESS DISTRIBUTION BY GROUP 
85 
MICRA UNCERTAINTY BY GROUP 
MICRA POSITIVE EXPERIENCES DISTRIBUTION BY GROUP 
86 
MICRA DISTRESS SCORES BY GROUP (1 & 2) 
MICRA UNCERTAINTY SCORES BY GROUP (1 & 2) 
87 
MICRA POSITIVE EXPERIENCE SCORES BY GROUP (1 & 2) 
MICRA DISTRESS SCORES BY RESULT TYPE (Positive (1) & Negative (0)) 
88 
MICRA UNCERTAINTY SCORES BY RESULT TYPE (Positive (1) & Negative (0)) 
MICRA POSITIVE EXPERIENCE SCORES BY RESULT TYPE (Positive (1) & Negative (0)) 
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